

Takamitsu Sasaki, Ph.D.

Assistant Professor,
Department of Molecular Toxicology,
School of Pharmaceutical Sciences, University of Shizuoka,
52-1 Yada, Suruga-ku, Shizuoka 422-8526, JAPAN

Telephone/fax: +81-54-264-5683

E-mail: t-sasaki@u-shizuoka-ken.ac.jp

Url; <http://w3pharm.u-shizuoka-ken.ac.jp/eisei/>

Education

- 2009 Ph.D. (Pharmaceutical Science), Tohoku Pharmaceutical University
2003 M.S. (Pharmaceutical Science), Tohoku Pharmaceutical University
2001 B.S. (Pharmaceutical Science), Tohoku Pharmaceutical University

Professional Experiences

- | | |
|---------------------|--|
| Aug. 2015-Present | Assistant Professor, University of Shizuoka, School of Pharmaceutical Sciences |
| Apr. 2015-Jul. 2015 | Research Assistant Professor, Tohoku Pharmaceutical University |
| Apr. 2014-Mar. 2015 | Postdoctoral Fellow, National Cancer Institute/ National Institutes of Health |
| Apr. 2011-Mar. 2014 | Research Assistant Professor, Tohoku Pharmaceutical University |
| Apr. 2004-Mar. 2011 | Research Assistant, Tohoku Pharmaceutical University |
| Apr. 2003-Mar. 2004 | Pharmacist, Department of Pharmacy, Showa Hospital |

Research Interests

Transcriptional regulation of drug metabolizing enzymes
Mechanism of drug-induced liver injury
Generation of human induced pluripotent stem cells-derived hepatocyte-like cells
Development of *in silico/in vitro* prediction models for safety assessment of chemical compounds

Membership in professional societies

2016-	The International Society for Alternative to Animal Experiments	Member
2015-	The Japanese Society of Toxicology	Member
2006-	The International Society for the Study of Xenobiotics	Member
2004-	The Japanese Society of Clinical Pharmacology and Therapeutics	Member
2001-	The Pharmaceutical Society of Japan	Member
2001-	The Japanese Society for the Study of Xenobiotics	Member

Academic Awards

2015	Best Article Award, Japanese Society of Pharmaceutical Health Care and Sciences
2014	DMPK Editor's Award for the Most Excellent Article in 2013
2012	Best Poster Award, Japanese Society for the Study of Xenobiotics Meeting
2007	Young Investigator's Award, Pharmaceutical Society of Japan (Tohoku branch)

Publications

Original articles (selected)

1. Activation of p38 Mitogen-Activated Protein Kinase by Clotrimazole Induces Multidrug Resistance-Associated Protein 3 Activation through a Novel Transcriptional Element. Sasaki T, Inami K, Numata Y, Funakoshi K, Yoshida M, Kumagai T, Kanno S, Matsui S, Toriyabe T, Yamazoe Y, Yoshinari K, Nagata K. *J Pharmacol Exp Ther.*, 31, 102-109, 2016.
2. CYP2A13 Genetic Polymorphisms in Relation to the Risk of Bladder Cancer in Japanese Smokers. Kumondai M, Hosono H, Orikasa K, Yoichi A, Sugimura H, Ozono S, Sugiyama T, Takayama T, Sasaki T, Hirasawa N, Hiratsuka M. *Biol Pharm Bull.*, 39, 1683-1686, 2016.
3. Indirubin, a component of Ban-Lan-Gen, activates CYP3A4 gene transcription through the human pregnane X receptor. Kumagai T, Aratsu Y, Sugawara R, Sasaki T, Miyairi S, Nagata K. *Drug Metab. Pharmacokinet.*, 31, 139-145, 2016.
4. Genetic Polymorphisms of CYP2A6 in a Case-Control Study on Bladder Cancer in Japanese Smokers. Kumondai M, Hosono H, Orikasa K, Yoichi A, Sugimura H, Ozono S, Sugiyama T, Takayama T, Sasaki T, Hirasawa N, Hiratsuka M. *Biol*

Pharm Bull., 39, 84-89, 2016.

5. Development of a highly reproducible system to evaluate inhibition of cytochrome P450 3A4 activity by natural medicines. Sato Y, Sasaki T, Takahashi S, Kumagai T, Nagata K. *J Pharm Pharm Sci.*, 18, 316-327, 2015.
6. Simultaneous evaluation of human CYP3A4 and ABCB1 induction by reporter assay in LS174T cells, stably expressing their reporter genes. Inami K, Sasaki T, Kumagai T, Nagata K. *Biopharm Drug Dispos.*, 36: 139-147, 2015.
7. A questionnaire survey of health food utilization by patients and consumers visiting pharmacies and assessment of whether the health foods noted in this survey inhibit CYP2D6. Sasaki T, Kumagai T, Sasaki H, Inami K, Sato Y, Takahashi S, Matsunaga T, Tokin M, Hosokawa M, Ohmori S, Nagata K. *Jpn. J. Pharm. Health Care Sci.*, 40: 488-499, 2014
8. An efficient method for differentiation of human induced pluripotent stem cells into hepatocyte-like cells retaining drug metabolizing activity. Kondo Y, Iwao T, Nakamura K, Sasaki T, Takahashi S, Kamada N, Matsubara T, Gonzalez FJ, Akutsu H, Miyagawa Y, Okita H, Kiyokawa N, Toyoda M, Umezawa A, Nagata K, Matsunaga T, Ohmori S. *Drug Metab. Pharmacokinet.*, 29: 237-243, 2014.
9. Hepatocyte nuclear factor 6 activates the transcription of CYP3A4 in hepatocyte-like cells differentiated from human induced pluripotent stem cells. Sasaki T, Takahashi S, Numata Y, Narita M, Tanaka Y, Kumagai T, Kondo Y, Matsunaga T, Ohmori S, Nagata K. *Drug Metab. Pharmacokinet.*, 28: 250-259, 2013.
10. Polycyclic aromatic hydrocarbons activate CYP3A4 gene transcription through human pregnane X receptor. Kumagai T, Suzuki H, Sasaki T, Sakaguchi S, Miyairi S, Yamazoe Y, Nagata K. *Drug Metab. Pharmacokinet.*, 27: 200-206, 2012.
11. Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Tamaki Y, Arai T, Sugimura H, Sasaki T, Honda M, Muroi Y, Matsubara Y, Kanno S, Ishikawa M, Hirasawa N, Hiratsuka M. *Drug Metab. Pharmacokinet.*, 26: 516-522, 2011.
12. Functional characterization of genetic polymorphisms identified in the promoter region of the xanthine oxidase gene. Kudo M, Sasaki T, Ishikawa M, Hirasawa N, Hiratsuka M. *Drug Metab. Pharmacokinet.*, 25: 599-604, 2010.

13. Construction of a system that simultaneously evaluates CYP1A1 and CYP1A2 induction in a stable human-derived cell line using a dual reporter plasmid. Sato W, Suzuki H, Sasaki T, Kumagai T, Sakaguchi S, Mizugaki M, Miyairi S, Yamazoe Y, Nagata K. *Drug Metab. Pharmacokinet.*, 25: 180-189, 2010.
14. Genetic variations in the HGPRT, ITPA, IMPDH1, IMPDH2, and GMPS genes in Japanese individuals. Kudo M, Saito Y, Sasaki T, Akasaki H, Yamaguchi Y, Uehara M, Fujikawa K, Ishikawa M, Hirasawa N, Hiratsuka M. *Drug Metab. Pharmacokinet.*, 24: 557-564, 2009.
15. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Sakuyama K, Sasaki T, Ujiie S, Obata K, Mizugaki M, Ishikawa M, Hiratsuka M. *Drug Metab. Dispos.*, 36: 2460-2467, 2008.
16. Possible relation between the risk of Japanese bladder cancer cases and CYP4B1 genotype. Sasaki T, Horikawa M, Orikasa K, Sato M, Arai Y, Mitachi Y, Mizugaki M, Ishikawa M, Hiratsuka M. *Jpn. J. Clin. Oncol.*, 38: 634-640, 2008.
17. Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2 - *24). Ujiie S, Sasaki T, Mizugaki M, Ishikawa M, Hiratsuka M. *Pharmacogenet. Genomics.*, 18: 887-893, 2008.
18. Functional characterization of human xanthine oxidase allelic variants. Kudo M, Moteki T, Sasaki T, Konno Y, Ujiie S, Onose A, Mizugaki M, Ishikawa M, Hiratsuka M. *Pharmacogenet. Genomics.*, 18: 243-251, 2008.
19. Genetic polymorphisms and haplotype structures of the human CYP2W1 gene in a Japanese population. Hanzawa Y, Sasaki T, Mizugaki M, Ishikawa M, Hiratsuka M. *Drug Metab. Dispos.*, 36: 349-352, 2008.
20. Characterization of human cytochrome P450 enzymes involved in the metabolism of cilostazol. Hiratsuka M, Hinai Y, Sasaki T, Konno Y, Imagawa K, Ishikawa M, Mizugaki M. *Drug Metab. Dispos.*, 35: 1730-1732, 2007.
21. Genetic polymorphism of aldehyde oxidase in Donryu rats. Itoh K, Masubuchi A, Sasaki T, Adachi M, Watanabe N, Nagata K, Yamazoe Y, Hiratsuka M, Mizugaki M, Tanaka Y. *Drug Metab. Dispos.*, 35: 734-739, 2007.
22. Genetic polymorphisms and haplotype structures of the CYP4A22 gene in a Japanese population. Hiratsuka M, Nozawa H, Katsumoto Y, Moteki T, Sasaki T, Konno Y, Mizugaki M. *Mutat. Res.*, 599: 98-104, 2006.

23. Three novel single nucleotide polymorphisms of the human thiopurine S-methyltransferase gene in Japanese individuals. Sasaki T, Goto E, Konno Y, Hiratsuka M, Mizugaki M. *Drug Metab. Pharmacokinet.*, 26: 332-336, 2006.
24. Rat strain differences in stereospecific 2-oxidation of RS-8359, a reversible and selective MAO-A inhibitor, by aldehyde oxidase. Sasaki T, Masubuchi A, Yamamura M, Watanabe N, Hiratsuka M, Mizugaki M, Itoh K, Tanaka Y. *Biopharm. Drug Dispos.*, 27: 247-255, 2006.
25. Two novel single nucleotide polymorphisms (SNPs) of the CYP2D6 gene in Japanese individuals. Ebisawa A, Hiratsuka M, Sakuyama K, Konno Y, Sasaki T, Mizugaki M. *Drug Metab. Pharmacokinet.*, 20: 294-299, 2005.
26. Stereospecific oxidation of the (S)-enantiomer of RS-8359, a selective and reversible monoamineoxidase A (MAO-A) inhibitor, by aldehyde oxidase. Itoh K, Yamamura M, Muramatsu S, Hoshino K, Masubuchi A, Sasaki T, Tanaka Y. *Xenobiotica*, 35: 561-573, 2005.
27. Protein identification by peptide mass fingerprinting and peptide sequence tagging with alternating scans of nano-liquid chromatography/infrared multiphoton dissociation Fourier transform ion cyclotron resonance mass spectrometry. Kosaka T, Yoneyama-Takazawa T, Kubota K, Matsuoka T, Sato I, Sasaki T, Tanaka Y. *J. Mass Spectrom.*, 38: 1281-1287, 2003.

Review articles

1. Progression Alcoholic and Non-alcoholic Steatohepatitis: Common Metabolic Aspects of Innate Immune System and Oxidative Stress. Sakaguchi S, Takahashi S, Sasaki T, Kumagai T, Nagata K. *Drug Metab. Pharmacokinet.*, 26: 30-46, 2011.
2. Genetic testing for pharmacogenetics and its clinical application in drug therapy. Hiratsuka M, Sasaki T, Mizugaki M. *Clin. Chim. Acta*, 363: 177-186, 2006.